Two SPAC IPOs to Start May — Republic Digital Upsized to $264M and Copley at $150M. ClimateRock Extension Vote. Aimfinity Delisting. Distoken Deal Vote Postponed.
Boardroom Alpha SPAC Resources
– Full SPAC Listing
– SPAC SEC Filings
– Boardroom Alpha IPO & SPAC Intelligence Platform (7-Day Trial)
Daily SPAC Update
EXTENSION VOTES
CLRCF – CLIMATEROCK * extend from May 2, 2025 to November 2, 2025
OTHER SPAC NEWS
ALCY – ALCHEMY INVESTMENTS ACQUISITION CORP 1 * Auditor Change
DIST – DISTOKEN ACQUISITION CORP * Deal Vote Postponed
AIMAU – AIMFINITY INVESTMENT CORP I * Delisting
CLRCF – CLIMATEROCK * Vote Adjourned
AQU – AQUARON ACQUISITION CORP * Vote Postponed
NEW SPAC IPOs
May 01: RDAG – Republic Digital Acquisition Co $264M IPO
May 01: COPL – Copley Acquisition Corp $150M IPO
Apr 29: LCCC – Lakeshore Acquisition Iii Corp. $60M IPO
Apr 29: TACO – Berto Acquisition Corp $261M IPO
Apr 28: DAAQ – Digital Asset Acquisition Corp. $150M IPO
Apr 28: RAAQ – Real Asset Acquisition Corp. $150M IPO (+underwriter overallotment: $22.5M)
SPAC DEALS ANNOUNCED
Apr 28 | BKHA – Black Hawk Acquisition Corp + Vesicor Therapeutics, Inc.
ABOUT Vesicor Therapeutics, Inc.
Vesicor was founded in 2008 in San Gabriel, California by Luo Feng, Ph.D. The Company is an early development stage biotechnology company focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles.
The Company’s first product candidate is ecm-RV/p53. This is a genetically engineered cellular microvesicle (“ecm”) non-viral nanoparticle RNA vesicle (“RV”) that is loaded with in vitro transcribed p53 mRNA. Although Vesicor’s ecm-RV/p53 drug candidate is unapproved for use in Japan and the United States, it has been administered to multiple patients in Tokyo, Japan since 2018 under the Japan Medical Practitioner’s Act, also known as Advanced Medical Care B. This mechanism allows unapproved drugs to be used under a physician’s discretion. The Company’s drug candidate has been used in multiple patients with advanced breast, pancreatic, prostate, lung and colorectal cancer. Vesicor believes that its ecm-RV/p53 drug candidate has broad therapeutic potential across a range of solid tumors. The Company intends to begin preclinical testing in the U.S., submit an investigational new drug (“IND”) application to the FDA and then to begin clinical trials, which efforts are expected to commence in 2026.
SPAC MOVERS
YESTERDAY’S TOP SPAC GAINERS
28.68% ~ $ 42.13 | CEP – CANTOR EQUITY PARTNERS INC (Announced)
17.08% ~ $ 19.26 | AIMAU – AIMFINITY INVESTMENT CORP I (Announced)
7.86% ~ $ 11.25 | CHEB – CHENGHE ACQUISITION II CO (Announced)
7.63% ~ $ 10.01 | BOWN – BOWEN ACQUISITION CORP (Announced)
7.56% ~ $ 11.67 | HCVI – HENNESSY CAPITAL INVESTMENT CORP VI (Announced)
YESTERDAY’S TOP SPAC LOSERS
-9.95% ~ $ 11.50 | MSSA – METAL SKY STAR ACQUISITION CORP (Pre-Deal)
-5.93% ~ $ 11.43 | DECA – DENALI CAPITAL ACQUISITION CORP (Announced)
-2.36% ~ $ 11.18 | YOTA – YOTTA ACQUISITION CORP (Announced)
-1.91% ~ $ 12.85 | DMYY – DMY SQUARED TECHNOLOGY GROUP INC (Pre-Deal)
-1.67% ~ $ 11.75 | TBMC – TRAILBLAZER MERGER CORP I (Announced)
LATEST SPAC IPO PERFORMANCE
May 01 | RDAG – Republic Digital Acquisition Co
May 01 | COPL – Copley Acquisition Corp
Apr 29 | LCCC – Lakeshore Acquisition III Corp.
Apr 29 | TACO – Berto Acquisition Corp
Apr 28 | DAAQ – Digital Asset Acquisition Corp.
Apr 28 | RAAQ – Real Asset Acquisition Corp.
Apr 24 | $ 10.01 | CHAC – Crane Harbor Acquisition Corp.
Apr 24 | $ 10.13 | IPCX – Inflection Point Acquisition Corp. III
Apr 23 | $ 10.10 | NPAC – New Providence Acquisition Corp. III
Apr 22 | $ 10.01 | TVA – Texas Ventures Acquisition III Corp
Apr 10 | $ 10.03 | TACH – Titan Acquisition Corp.
Apr 03 | $ 10.02 | SZZL – Sizzle Acquisition Corp. II
Apr 03 | $ 10.02 | SOUL – Soulpower Acquisition Corp.
Apr 01 | $ 10.10 | SDHI – Siddhi Acquisition Corp